6% growth masks profit slide; cost recovery path clear for FY28
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 7/10
Grade B
Solar DHF ramp on track; HFC-32 60% complete, on schedule. Q1 margin pressure acknowledged and explained; cost pass-through mechanism transparent but recovery not yet visible in delivered Q1 results.
Cautiously Optimistic
next 1–2 quarters
Very Optimistic
multi-year
Q1 delivered 6.3% revenue growth backed by solar grade DHF ramp and net debt-free balance sheet, but PAT fell 12.9% as input cost inflation (sulphur ₹30→₹105, power/fuel spike) compressed margins with a 30-45 day pass-through lag. HFC-32 multi-year growth catalyst is concrete (65% pre-contracted, 60% built, ₹395 Cr capex, Nov commissioning, path to 25% margins FY28), but near-term execution and cost recovery are watch-points.
₹187.2 Cr
Revenue · +6.3% YoY₹16.8 Cr
Reported PAT · −12.9% YoYCompressing
Margins · vs guidance: CorroboratedDid the claims hold up?
6% YoY revenue growth to ₹187 Cr (15% pricing + 6-8% volumes)
MET₹187.2 Cr, +6.3% YoY; driven by solar grade DHF and AHF volumes
EBITDA margins 15.3% impacted by sulphur/power costs; 30-45 day pass-through recovery lag
OVERSTATEDOPM 15.3% aligns with prior 15-18% range; PAT down 12.9% shows cost impact not yet recovered
PAT ₹16.8 Cr impacted by elevated sulphur (₹30→₹105) and power costs plus deferred tax adjustment
METPAT ₹16.8 Cr (-12.9% YoY vs ₹19.4 Cr Q1 FY26); cost explanation consistent with delivered result
Solar grade DHF fully ramped, 85% contracted for 3.5 years; new demand from solar players
METSolar grade driving revenue growth; capacity utilization disclosed; revenue growth consistent with ramp narrative
HFC-32 project 60% complete, ₹315 Cr committed of ₹395 Cr, commissioning by Nov-end Q3
METProject tracking on schedule; capex ₹395 Cr (vs prior ₹495 Cr); ₹100 Cr cash outflow Q1 consistent with commitment
Earnings quality
What changed since the last call
FY27-28 revenue growth guidance quantified
UpgradeNew: 30% FY27 growth, 60% FY28 growth. Prior call only mentioned ₹3,000-3,500 Cr long-term vision. Specificity adds credibility.
HFC-32 capex reduced
UpgradeProject capex ₹395 Cr vs prior ₹495 Cr (₹100 Cr improvement via execution optimization). ₹315 Cr committed as of Q1; no cost overrun expected.
Capex roadmap detailed
New4-year capex ₹1,500-1,700 Cr: solar DHF (₹30-40 Cr), AHF (₹120 Cr), electronic grade (₹150 Cr), later HFOs & fluoropolymers. Prior call vague on future capex.
FY28 margin target quantified
UpgradeNew: 25% blended EBITDA margin FY28 (existing business 16-20%, R-32 ~30%). Prior call only hinted at long-term margin potential.
Margin guidance reaffirmed
MaintainedExisting business 16-19% from Q2 onwards (prior 15-18%); R-32 ~30%. Core range maintained; Q4 FY27 blended 21-22%.
The Q&A
Q&A was substantive and detailed. Analysts pressed R-32 contract backing (confirmed 2 firm + 1 MoU, take-or-pay, 5-7 years, 75% exports). Sulphur hedging questioned—management disclosed no formal hedging, only pass-through lag mechanism. Electronic grade timeline partly hedged (1-1.5 year approval cycle, tech tie-up status unclear). Fluoropolymer strategy opaque ('confidential', 2-3 options). Overall: management held numbers well, but hedging on forward-looking items (e-chem timing, fluoropolymer product) suggests execution uncertainty.
FY27-28 growth & margins — Meet Gada, Individual Investor
AnsweredFY27 30% growth, FY28 60%+ growth. Q2-Q3 margins 16-19%, full year FY27 blended 21-22%; FY28 ~25% once R-32 operational.
Sulphur volatility — Meet Gada, Individual Investor
PartialNo formal hedging disclosed. Sulphur ₹30→₹105; pass-through mechanism 30-45 day lag; availability not an issue; multiple supplier geographies.
R-32 ROCE & contract — Aakash, Investec
AnsweredHFC-32 margin ~30%; blended business ~25%. No change from prior call guidance.
Solar DHF moat durability — Aakash, Investec
AnsweredMix own + licensed tech; 10 PPB impurity spec a high barrier; 4-5 month learning curve; customer approvals lengthy. Only producer today; approved by all majors.
6% growth split — Sujal Jhanwar, Growmore PMS
Answered~15% pricing growth + 6-8% volume growth = 6% net. Blended from product mix.
Future capex plans — Sujal Jhanwar, Growmore PMS
AnsweredSolar grade ₹30-40 Cr, AHF ₹120 Cr, e-chem ₹150 Cr (~₹300 Cr total). Start after R-32 commissioning (Dec); 12-15 month horizon.
R-32 volume ramp — Siddharth Gadekar, Equirus
AnsweredFY27 Q4: 65-70% utilization (startup phase). FY28: 80-85% conservative. Management confident of 90%+ utilization.
AHF interim decline — Sanjesh Jain, ICICI Securities
Answered30,000 MT HF total; R-32 takes 15,000 MT internal; ~7,000-8,000 MT AHF external sales remain. Yes, interim AHF revenue decline; expansion capex 12-15 month lag.
R-32 pricing strategy — Dhruv Bajaj, GrowthSphere
Answered$5.5/kg contracted (formula-based, cost pass-through included); 5-7 year terms; speed-to-market priority. 65% fixed EBITDA/ton margin; 30% spot play.
Electronic grade timeline — Ankur Periwal, Axis Capital
PartialEvaluating multiple tech tie-ups; immediate priority solar grade. E-chem capex ₹150 Cr broad ±10%. Capex starts post-R-32 commissioning.
R-32 project status — Preet Jain, Niveshaay
Answered60% complete; 30-35% remaining by Nov; commissioning Nov-end. Machines arriving Sept 10, erection 20-25 days. Product approved (lab → pilot → third-party tested); no cost overruns expected.
AHF customer segments — Preet Jain, Niveshaay
Answered1/3 solar grade, 1/3 pharma/agro/refrigerant, 1/3 surface treatment/steel/glass/inorganic fluorides. Named: Jindal, Piramal, Cohizon, Tata, Adani, Premier Energies.
Solar DHF expansion — Sanjesh Jain, ICICI Securities
PartialPlan to almost double; 85% currently contracted; new solar players driving demand. Capex details forthcoming.
Fluoropolymer strategy — Sanjesh Jain, ICICI Securities
DodgedConfidential; 2-3 options under development; will not pursue commodity fluoropolymers. Contract-led, high-niche products only.
HF demand outlook — Rudraksh Gupta, Navneet
AnsweredDomestic HF demand 30,000-35,000 MT/year. Peer HF capacity additions pose no threat: 1/3 for solar (uncontested), 1/3 captive R-32, 1/3 dispersed applications.
China competition — Rudraksh Gupta, Navneet
AnsweredAHF controlled, dual-use chemical; stringent regulatory approvals, end-use docs, license requirements; logistic challenges (ISO tanks return empty). No pricing pressure observed.
R&D capability — Karan Kamdar, Choice Institutional
AnsweredHead: Dr. L.R. Ravichandran (40+ years); 10+ professionals, 3-4 PhDs; 5-8 products pipeline. R&D capex ₹7-8 Cr last 1.5 years; revenue expense ₹5-6 Cr.
Solar DHF competitive moat — Nirvana Laha, Badrinath Holdings
AnsweredStrict <10 PPB impurity spec; capex required; 4-5 month learning curve. Doesn't come day 1. E-chem 1,000x harder; will need tech tie-up.
E-chem grade AHF — Nirvana Laha, Badrinath Holdings
PartialApproval cycle primary (1-1.5 years semicon); will tie up with tech suppliers to reduce time. Own capex investment; customer-led model.
Guidance
FY27: 30% revenue growth; FY28: 60%+ revenue growth
MediumFY27 assumes R-32 Q4 launch (3 months contribution) + solar DHF ramp. FY28 assumes full-year R-32 at 80-85% utilization. Dependent on execution.
5-year revenue target: ₹3,000-3,500 Cr (vs ₹187 Cr current)
MediumImplies 16-19x growth, ~65-75% CAGR. Hinges on R-32 (₹900-1,000 Cr potential), solar DHF expansion, AHF, e-chem, HFOs, fluoropolymers.
FY27 EBITDA margin 21-22% blended (existing 16-19%, R-32 Q4 higher)
HighExisting business 16-19% achievable once cost pass-through completes (30-45 day lag). R-32 Q4 will be higher margin but limited 3-month ramp.
FY28 EBITDA margin ~25% once HFC-32 fully operational
MediumAssumes R-32 80-85% utilization. HFC-32 project margin ~30%, existing business ~18-20%. Blended ~25%.
HFC-32 capex ₹395 Cr; ₹315 Cr committed Q1
High60% construction done; ₹100 Cr cash outflow Q1. Machines arriving Sept 10; erection 20-25 days. Commissioning Nov-end. No overruns expected.
FY27-28 capex: solar ₹30-40 Cr, AHF ₹120 Cr, e-chem ₹150 Cr (~₹300 Cr)
MediumStarts post-R-32 commissioning (Dec). Phased over 12-15 months. Broad estimates ±10%.
4-year capex plan: ₹1,500-1,700 Cr
MediumCovers solar expansion, AHF expansion, e-chem, HFOs, high-performing fluoropolymers. Phased 2027-2031.
Risks the call surfaced
Execution risk—HFC-32
Medium₹395 Cr HFC-32 project 60% done; commissioning targeted Nov-end. Machines arrive Sept 10, erection 20-25 days. Any delay would push ramp-up timeline and FY28 revenue/margin targets.
Input cost volatility
HighSulphur price spiked ₹30→₹105 in Q1; power/fuel costs elevated (captive plant downtime for maintenance). While pass-through mechanism exists (30-45 days), Q1 PAT fell 12.9% YoY despite revenue growth. Geopolitical risk ongoing.
R-32 contract durability
Medium65% of R-32 capacity pre-contracted: 2 firm (1 Japanese, 1 domestic OEM) + 1 MoU (5,000 MT). If demand weakens or prices fall sharply below contract midpoint (currently $5.5/kg vs spot $9-10), renegotiation risk exists.
Solar DHF competitive erosion
MediumTANFAC claims India monopoly in solar grade DHF. Barriers: 10 PPB impurity spec, capex, 4-5 month learning curve. If larger players (Ghcl, Solvay) enter, market dynamics shift. 6x-8x solar capacity growth provides room, but margin pressure possible.
Electronic grade AHF uncertainty
MediumE-chem AHF requires 100 PPT impurity (1,000x harder than solar grade). Management targeting tech tie-up to accelerate. 1-1.5 year approval cycle post-launch adds delay. Capex ₹150 Cr broad ±10% estimate; customer qualification uncertain.
Management
Score 8/10. Clear on execution metrics (R-32 60% done, solar 85% contracted, Q4 commissioning timeline). Transparent on near-term cost pressures and lag. Quantified growth guidance (30% FY27, 60% FY28) adds credibility. Hedging on electronic grade timeline (approval cycle 1-1.5 years, tech tie-up under eval) and fluoropolymer specifics ('confidential'). Solar grade DHF both phases on schedule, ramping well. HFC-32 60% complete, commissioning on track for Nov-end. Capex optimized (₹395 Cr vs ₹495 Cr prior). Track record: on-time solar phases, on-track R-32, slight Q3→Q4 slip (immaterial). Mix of strong delivery + cautious tone on future timelines.
1 · Nov-Dec 2026
HFC-32 plant commissioning; product launch; ramp-up through Feb; customer approvals complete
2 · Q2 FY27
Cost pass-through recovery kicks in (30-45 day lag); power costs stabilize post-maintenance shutdown
3 · FY28 start
HFC-32 full ramp (80-85% utilization); ₹900-1,000 Cr revenue generation; 25% EBITDA margins achieved
HFC-32 multi-year growth catalyst is concrete (65% pre-contracted, 60% built, ₹395 Cr capex, Nov commissioning, path to 25% margins FY28), but near-term execution and cost recovery are watch-points.
Tanfac Q1: revenue up 6% YoY but PAT slips 13% as power costs, higher tax bite margins
PAT -12.93% YoY · revenue +6.35% · margins compressing
₹187.18 Cr
+6.35% YoY
₹16.85 Cr
-12.93% YoY
8.96%
-2pp YoY
₹8.43
Tanfac Industries posted standalone Q1 FY27 (quarter ended June 2026) revenue of ₹187.18 Cr, up 6.3% YoY from ₹176.00 Cr but down 3.1% sequentially from ₹193.08 Cr — a mild topline expansion that failed to reach the bottom line. Net profit fell to ₹16.85 Cr, down 12.9% YoY (₹19.35 Cr) and 6.6% QoQ (₹18.04 Cr), with EPS at ₹8.43 (restated post the 1:2 split) against ₹9.70 a year ago. The headline profit decline overstates the operating slippage: at the PBT level the fall was only 3.6% YoY (₹23.75 Cr vs ₹24.65 Cr). The gap is a tax effect — the year-ago quarter carried a ₹0.90 Cr prior-year tax write-back that lifted its PAT, and this quarter's effective tax rate normalised to 29.1% (vs ~21.5%). Adjusting the year-ago base for that one-off, underlying PAT is down ~8.7%, so the print is a genuine but moderate profit decline, not a sharp collapse.
Q1 FY-2027 vs prior quarters
Margins did the damage on the cost side. Net profit margin compressed to ~9.0% from 10.9% YoY, and operating margin eased to ~15.3% (from 16.5% YoY / 15.7% QoQ). The squeeze sits mainly on power and fuel, which jumped ~30% YoY to ₹16.65 Cr (from ₹12.81 Cr), alongside raw-material cost up 13% on revenue up only 6% and depreciation up 21% to ₹4.70 Cr as recent capacity came on stream. Lower finance cost (₹0.97 Cr vs ₹1.39 Cr) provided a partial offset. The ~15.3% operating margin lands at the bottom of management's prior 15-18% EBITDA guidance from the Q4 concall — technically within range, but the low end, and the confident, cautiously-optimistic tone struck on that call is only partially borne out by a quarter where volume/price gains were eaten by input inflation.
The stock went into the print at ₹2,720, up 11.5% over the past month of trading.
Management guides for operating EBITDA margins to be range-bound at 15-18% for the existing business, supported by the ramp-up of solar grade DHF revenues. A significant INR 495 crore capex for HFC-32 and other products is underway, with commissioning targeted for Q3 FY27, underpinning a long-term revenue ambition of I
— This quarter: met
The result lands amid heavy corporate action rather than operating catalysts: the quarter saw a completed ₹250 Cr QIP (12,58,918 shares at ₹1,985.83) plus a preferential issue, expanding paid-up equity to ₹10.60 Cr and diluting the per-share base — the QIP proceeds sat in escrow/FDs at quarter-end, pending deployment. This funds the ₹495 Cr HFC-32 and downstream fluorochemicals capex (a separate 20,000 MTPA fluorinated-products line at ₹49,500 Lakh is also under implementation), with commissioning guided for Q3 FY27 and underpinning management's five-year ₹3,000-3,500 Cr revenue ambition. No brokerage consensus exists for this small-cap, so there is no street benchmark to beat or miss; the earnings call is set for July 27. Net: a soft quarter where the growth engine is still capex-in-progress and current margins are being tested by power costs.
W1
HFC-32 and downstream fluorochemicals capex (₹495 Cr) commissioning on schedule for Q3 FY27 — the key volume trigger
W2
Whether operating margin recovers into the 15-18% guided band or power/raw-material inflation keeps it pinned at the ~15% floor
W3
Deployment of the ₹250 Cr QIP proceeds still parked in escrow/FDs at quarter-end, and solar-grade DHF ramp management flagged as the near-term margin support
A quarter in cost-recovery limbo; HFC-32 is the step-change
Revenue grew 6.3%, but net profit fell 12.9% YoY as input costs—sulphur spiked 3.5x, power surged—outpaced pricing recovery. Management's cost pass-through mechanism is credible; Q1 results don't yet prove it works.
₹187.2 Cr
+6.3% YoY
₹16.8 Cr
-12.9% YoY
-3.1%
vs. Q4 FY26
-6.6%
temporary cost factors
The headline says revenue is growing, the bottom line says it isn't. TANFAC's Q1 results expose a structural gap: top-line recovered to 6.3% YoY growth (driven by solar grade DHF ramp and pricing), but net profit fell 12.9% as input costs—sulphur spiked from ₹30 to ₹105 per unit, power surged—compressed margins faster than the company could pass them through. Management's explanation is sound. But Q1's delivered results don't yet show the cost recovery working.
Where the profit went: input inflation + lag
EBITDA margin held at 15.3% (flat YoY), well within prior guidance of 15–18%. But EBITDA is gross of fixed costs and finance charges. Below-the-line, the hit compounds: geopolitical sulphur spike to ₹105, elevated power and fuel costs (partly driven by captive power plant maintenance downtime), and a deferred tax adjustment all flow to PAT. Management disclosed a 30–45 day cost pass-through lag—contracts repriced monthly or quarterly, not instantaneously. In Q1, that lag appears unresolved: the 15.3% EBITDA margin vs. 9.0% net margin widens to a 6.3 percentage point drag, versus 5.9pp in Q1 FY26. The gap suggests cost recovery has not yet materialized in the delivered quarter.
6% YoY revenue growth from pricing (15%) + volumes (6–8%)
₹187.2 Cr, +6.3% YoY; solar grade DHF and AHF volumes confirmed ramping
Supported
EBITDA margin 15.3%, impacted by sulphur (₹30→₹105) and power; 30–45 day pass-through lag
OPM 15.3% aligns with 15–18% prior guidance; PAT fell 12.9% shows cost not yet recovered
Supported (lag unresolved)
PAT ₹16.8 Cr impacted by elevated costs + deferred tax adjustment
PAT ₹16.8 Cr vs. ₹19.4 Cr Q1 FY26; cost explanation consistent
Supported
Solar grade DHF fully ramped, 85% contracted for 3.5 years; new demand from solar players
Solar driving revenue growth; 85% contracted confirmed; new customer cohort adds Aug–Dec
Supported
HFC-32 project 60% complete; ₹395 Cr capex (vs. ₹495 Cr prior); Nov commissioning
Project on track; ₹315 Cr committed of ₹395 Cr; machines arriving Sept 10; erection 20–25 days
Supported
What changed from the last call
FY27–28 growth now explicit: 30% FY27, 60%+ FY28 (vs. prior long-term vision only)
HFC-32 capex reduced ₹100 Cr: ₹395 Cr vs. ₹495 Cr prior (execution optimization)
Capex roadmap detailed: 4-year ₹1,500–1,700 Cr (solar ₹30–40 Cr, AHF ₹120 Cr, e-chem ₹150 Cr, others)
FY28 margin target quantified: 25% blended EBITDA (existing 16–20%, HFC-32 ~30%)
Core margin range reaffirmed: existing business 16–19% from Q2 onwards (prior 15–18%)
The long-term thesis: a step-change in FY28
Beneath Q1's cost headwind sits a transformational capex cycle. HFC-32 (refrigerant R-32, low-GWP replacement for legacy coolants) is 60% built, commissioning by Nov–Dec 2026. Management has pre-contracted 65% of capacity for 5–7 years on take-or-pay terms: 2 firm contracts (Japanese customer, domestic OEM) + 1 MoU converting imminently. The facility targets ~30% EBITDA margin vs. existing business 16–20%, making it the growth engine for FY27 onwards. Revenue potential: ₹900–1,000 Cr annually at full run. FY27 guidance targets 30% blended revenue growth (R-32 Q4 ramp + solar DHF continued push); FY28 targets 60%+ growth once R-32 hits 80–85% utilization. By FY28, blended EBITDA margin reaches ~25%—the margin uplift this quarter is waiting for.
Solar grade DHF (both phases commissioned, 85% contracted) is a structural moat: the 10 parts-per-billion impurity spec creates barriers (capex, 4–5 month learning curve, lengthy customer approvals). TANFAC is India's sole producer today. Tailwind is 6–8x domestic solar wafer/chip capacity growth (35 GW → 210 GW by FY29), driving proportionate DHF demand. AHF (commercial hydrofluoric acid) faces interim headwind: R-32 launch diverts 15,000 MT of 30,000 MT HF capacity to internal use, cutting external AHF sales from ~₹75 Cr to ~₹35–40 Cr. But ₹120 Cr AHF expansion capex (starting post-R-32 commissioning, 12–15 month lag) replaces lost volume. E-chem (electronic grade AHF for semiconductor fabs) is a greenfield play: 1–1.5 year approval cycle, tech tie-up under evaluation, 100 PPT impurity (1,000x harder than solar grade). Revenue potential long-term is significant; timeline uncertain.
The bull-bear ledger
Bull: Backward-integrated HF platform (30,000 MT capacity, India's largest) + monopoly solar grade positioning + R-32 fully contracted (65%) + net debt-free balance sheet (₹250 Cr QIP, ₹100 Cr preferential issue approved)
Bull: HFC-32 execution track record solid: 60% complete on schedule, machines arriving Sept 10, erection 20–25 days, no cost overruns, product third-party tested
Bull: Quantified 5-year target ₹3,000–3,500 Cr (16–19x current, ~65–75% CAGR) with concrete mechanisms: solar DHF expansion, R-32 ramp, e-chem, HFOs, fluoropolymers
Bear: Q1 PAT fell 12.9% YoY despite revenue growth—cost pass-through lag unresolved; recovery visibility missing
Bear: Sulphur hedging nonexistent; only mechanism is 30–45 day pass-through lag. Geopolitical tail risks remain (West Asia situation may not stabilize soon)
Bear: AHF revenue interim decline (external sales fall from ~₹75 Cr to ~₹35–40 Cr for 12–15 months until expansion capex) creates Q2 FY27–Q3 FY28 earnings headwind
Bear: R-32 MoU (5,000 MT offtake, 1/3 of 65% contracted base) not yet converted; customer concentration risk if demand softens
Bear: Solar DHF competitive moat (10 PPB spec, learning curve, capex) could erode if larger players (Ghcl, Solvay) enter; 6–8x capacity growth provides room but margin dilution possible
Risks, ranked by severity for a holder
HFC-32 execution delays or cost overruns
HighProject 60% complete, Nov–Dec commissioning targeted. Machines arriving Sept 10, erection 20–25 days tight. Any slip pushes ramp-up into H2 FY27 / Q1 FY28, derailing 30% FY27 & 60% FY28 growth targets. Margin step-up to 25% also delayed.
Input cost volatility (sulphur, power, fluorspar)
HighSulphur spiked ₹30→₹105 (3.5x). Q1 PAT fell 12.9% despite revenue growth, signaling margin compression is real. Only mitigation is 30–45 day pass-through lag; no formal hedging disclosed. Geopolitical risk (West Asia) ongoing. Spot moves can exceed contractual escalators.
R-32 contract durability & customer concentration
Medium65% capacity pre-contracted: 2 firm (Japanese, domestic OEM) + 1 MoU (5,000 MT). If end-market demand softens or prices fall sharply below $5.5/kg contract mid-point (vs. spot $9–10), renegotiation risk exists. MoU conversion not guaranteed imminently. Concentrated customer base amplifies risk.
AHF interim revenue decline
MediumR-32 launch (Dec 2026) diverts 15,000 MT HF to internal use. External AHF sales drop from ~₹75 Cr to ~₹35–40 Cr. Expansion capex (₹120 Cr) starts 12–15 months later. Creates revenue/margin gap Q2 FY27–Q3 FY28, headwind into FY28 growth guidance.
Solar grade DHF competitive entry
MediumTANFAC claims India monopoly. Barriers: 10 PPB impurity spec, capex, 4–5 month learning curve. If larger peers (Ghcl, Solvay, Arkema) enter, market dynamics shift. 6–8x solar capacity growth absorbs incremental supply, but margin compression likely if entrant offers cost advantage.
Electronic grade AHF timeline uncertainty
Low-Medium100 PPT impurity (1,000x harder than solar grade). Approval cycle 1–1.5 years. Tech tie-up under evaluation. Capex ₹150 Cr (broad ±10%). Customer qualification uncertain. May slip or encounter unexpected delays.
How the street is positioned
The stock was ₹2,720 closing the day before results. Day-1 post-announcement fell 4.41% on the profit miss. But by day 3 (+2.6%) and day 5 (+12.71%), the market recovered sharply—suggesting institutional re-entry as the long-term thesis (R-32 catalysts, margin recovery, capex roadmap) sank in. Current price ₹3,065.7 sits just 1.74% below its all-time high, in overbought territory (RSI 79.7). The stock has rallied 87.78% from its 52-week low. Volume trend is normal, not hyperactive.
Ownership is promoter-heavy: 51.81% promoter (unchanged), 0.03% FII, 0.33% DII. Institutional ownership is minimal; no recent FII/DII buying. The day-5 recovery suggests retail / domestic HNI re-engagement, not institutional conviction. A stock near all-time highs on minimal institutional backing and overbought technicals is vulnerable to a pullback on any stumble (missed cost pass-through in Q2, HFC-32 delay, sulphur spike renewed).
The debate
The honest read: This is a steady-execution story with a transformational capex step-change. Q1 is a transition quarter—cost headwinds peak, margin compression visible, but top-line fundamentals (solar DHF ramp, R-32 pre-contracted, pricing power) remain intact. The real earnings inflection comes in H2 FY27 (cost pass-through materializes, R-32 launches) and FY28 (full R-32 ramp, margin recovery to 25%). Execution risk is material (HFC-32 schedule, cost recovery timing, MoU conversion); the day-5 rally suggests the market is pricing in success. At ₹3,065.7, near all-time highs with overbought technicals and minimal institutional backing, the risk-reward is balanced. Holders should track Q2's cost pass-through visibility; new entrants should wait for evidence Q2 PAT recovers.
1 · Q2 cost pass-through recovery (the critical watch)
Is PAT growing again as cost lags resolve? If Q2 PAT shows reacceleration vs. Q1, cost recovery narrative is validated. If Q2 PAT is again flat or negative despite revenue growth, the 30–45 day lag hypothesis fails and margins remain under pressure.
2 · HFC-32 commissioning on track (Nov–Dec 2026)
Machines arrive Sept 10; erection 20–25 days. Any delay pushes ramp into H2 FY27 / Q1 FY28. Management must deliver on-time. Third-party product testing is complete; no regulatory risk expected. Watch for installation hiccups, supplier delays, or customer approval gaps.
3 · R-32 MoU conversion status (1 firm contract still pending)
The MoU (5,000 MT offtake, ~1/3 of 65% pre-contracted base) is not yet a binding contract. Management expected conversion 'very soon' on the call. Failure to convert would reduce secured capacity to 50%, add execution risk. Watch for announcement of formal contract signing.
4 · Solar grade DHF new customer wins (Aug–Dec 2026)
Management flagged new solar players driving demand. Watch for capacity expansion greenlight and contract announcements. Current 85% utilization is healthy; new adds offset any competitive entry risk. Revenue uplift would validate the structural solar tailwind narrative.
5 · AHF interim revenue decline (Q4 FY26–Q3 FY27)
Once R-32 launches (Dec 2026), external AHF sales drop to ~₹35–40 Cr from current ~₹75 Cr. This creates a predictable headwind into H1 FY27. Management must communicate the expansion capex timeline (12–15 months post-commissioning). Any further delays extend the gap.
TANFAC's Q1 result is neither a miss nor a home run—it is a transition quarter. Revenue growth is solid, backed by real operational progress (solar DHF ramp, R-32 60% built, ₹315 Cr capex deployed). Profit fell because input cost inflation outpaced pricing recovery by one quarter. That's friction, not fracture. The company's 30–45 day cost pass-through mechanism is credible and contractually embedded; Q2 results will prove whether it actually works.
The real story is not Q1. It is Nov–Dec 2026 (R-32 commissioning), Jan–Feb 2027 (first production ramp, customer qualifications), and FY28 (full utilization, 25% blended margins, 60% revenue growth potential). Management's quantified guidance (30% FY27, 60% FY28, ₹3,000–3,500 Cr 5-year vision) is credible: concrete capex plan (₹1,500–1,700 Cr), pre-contracted volume (65% R-32), execution track record solid (solar phases on-time, R-32 60% complete as promised). Risks are material—execution delays, cost volatility unhedged, AHF interim decline—but are visible and manageable.
At ₹3,065.7 (near all-time highs, overbought RSI), the stock has priced in execution success. Holders should hold through Q2 cost pass-through and R-32 commissioning (the proving catalysts). New entrants should wait for Q2 PAT recovery to confirm the margin thesis. The single number to track: Q2 adjusted PAT—if it grows vs. Q1 (after accounting for temporary items), the transformational thesis is on track.